Spending growth for simple medications used to treat common health problems is outstripping spending growth for pricey medications used to treat complex and chronic conditions, according to a new ...

McKesson's minimal exposure to US-Mexico-Canada tariffs and geopolitical tensions ensures stability. Read why MCK stock is a ...

Hims & Hers has risen since November 2024, outperforming the S&P 500. Click here to see why HIMS stock is a Buy.

CMS has published its final rule for Medicare Advantage and Part D in 2026, outlining a series of regulatory updates aimed at ...

The number of Americans taking cutting-edge weight-loss drugs like Ozempic, Wegovy and Zepbound has skyrocketed in recent ...

with average prices consistently exceeding $1,500 per prescription, results show. "Despite this, adoption remained limited, as only 1 in 250 U.S. adults without diabetes used a GLP-1 [drug] in ...

Prime to present seven studies and receive the 2024 JMCP Award for Excellence "Prime's second-year study on the real-world impact of GLP-1 drugs for ... large increases in prescription drug ...